Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer

Abstract

Liquid biopsies represent an attractive, minimally-invasive alternative to surgical sampling or complex imaging of breast cancer and breast cancer metastasis. Here we present a summary of the major biomarker components often evaluated in liquid biopsy samples from patients with breast cancer, including circulating tumor cells, circulating cell-free tumor DNA, and cancer-associated plasma proteins. We discuss recent advancements in methods of detection and use of these biomarkers in breast cancer. Finally, we highlight some of our own recent contributions to breast cancer liquid biopsy, including the identification and characterization of circulating Cancer Associated Fibroblasts.

Keywords

Liquid biopsy / breast cancer / cell-free tumor DNA / CTC / cancer associated fibroblast

References

[1] Ashworth TR.A case of cancer in which cells similar to those in the tumours were seen in the blood after death..Aust Med J1869;14:146

[2] Fleischhacker M.Circulating nucleic acids (CNAs) and cancer--a survey..Biochim Biophys Acta2007;1775:181-232

[3] Bettegowda C,Leary RJ,Wang Y.Detection of circulating tumor DNA in early- and late-stage human malignancies..Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[4] Dawson SJ,Murtaza M,Rueda OM.Analysis of circulating tumor DNA to monitor metastatic breast cancer..N Engl J Med2013;368:1199-209

[5] Garcia-Murillas I,Weigelt B,Hrebien S.Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer..Sci Transl Med2015;7:302ra133

[6] De Mattos-Arruda L.Cell-free circulating tumour DNA as a liquid biopsy in breast cancer..Mol Oncol2016;10:464-74 PMCID:PMC5528975

[7] Olsson E,George A,Howlin J.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease..EMBO Mol Med2015;7:1034-47 PMCID:PMC4551342

[8] Reinert T,Thomsen R,Vang S.Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery..Gut2016;65:625-34

[9] Coombes RC,Salari R,Armstrong A.Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence..Clin Cancer Res2019;25:4255-63

[10] McDonald BR,Sammut SJ,Ernst B.Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer..Sci Transl Med2019;11:eaax7392

[11] Bidard FC,Fehm T,Gisbert-Criado R.Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data..Lancet Oncol2014;15:406-14

[12] Rack B,Juckstock J,Hepp P.Circulating tumor cells predict survival in early average-to-high risk breast cancer patients..J Natl Cancer Inst2014;106: PMCID:PMC4112925

[13] Lucci A,Lodhi AK,Anderson AE.Circulating tumour cells in non-metastatic breast cancer: a prospective study..Lancet Oncol2012;13:688-95

[14] Smerage JB,Doyle GV,Brown ME.Assessment of circulating tumor cells in breast cancer patients undergoing neoadjuvant chemotherapy..J Clin Oncol2006;

[15] Saloustros E,Apostolaki S,Xyrafas A.Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse..Breast Cancer Res2011;13:R60 PMCID:PMC3218949

[16] Pachmann K,Kavallaris A,Schunemann S.Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring..Breast Cancer Res2005;7:R975-9 PMCID:PMC1410761

[17] Riethdorf S,Zhang L,Loibl S.Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial..Clin Cancer Res2010;16:2634-45

[18] Sparano J,Alpaugh K,Northfelt DW.Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial..JAMA Oncol2018;4:1700-6 PMCID:PMC6385891

[19] Cristofanilli M,Reuben J,Davis AA.The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper..Crit Rev Oncol Hematol2019;134:39-45

[20] Bidard FC,Dureau S,Bachelot T.Abstract GS3-07: clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: results of the phase III STIC CTC trial..Cancer Res2019;79:GS3-07

[21] Dai D,Tang H,Zhao Z.Nomograms for predicting the prognostic value of pre-therapeutic CA15-3 and CEA serum levels in TNBC patients..PLoS One2016;11:e0161902 PMCID:PMC4999206

[22] Tampellini M,Bitossi R,Alabiso I.Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients..Breast Cancer Res Treat2006;98:241-8

[23] Pons-Anicet DM,Mira R.Value of CA 15:3 in the follow-up of breast cancer patients..Br J Cancer1987;55:567-9 PMCID:PMC2001716

[24] Saw S,Lim SH,Lim C.Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice..Breast Cancer Res Treat2019;177:197-206

[25] Kramer S,Lang N.CA 125 is an indicator for pleural metastases in breast cancer..Anticancer Res1997;17:2967-70

[26] Di Gioia D,Nagel D,Stieber P.Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3..Clin Chim Acta2016;461:1-7

[27] Cohen SJ,Iannotti N,Sabbath KD.Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer..J Clin Oncol2008;26:3213-21

[28] Cristofanilli M,Budd GT,Stopeck A.Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer..J Clin Oncol2005;23:1420-30

[29] Yu M,Wittner BS,Smas ME.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition..Science2013;339:580-4 PMCID:PMC3760262

[30] Konigsberg R,Bises G,Gneist M.Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients..Acta Oncol2011;50:700-10

[31] Satelli A,Mitra A,Li S.Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response..Clin Chem2015;61:259-66 PMCID:PMC4360893

[32] Kaigorodova EV,Tashireva LA,Simolina EI.Heterogeneity of circulating tumor cells in neoadjuvant chemotherapy of breast cancer..Molecules2018;23: PMCID:PMC6017975

[33] Papadaki MA,Theodoropoulos PA,Georgoulias V.Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer..Mol Cancer Ther2019;18:437-47

[34] Esposito A,Criscitiello C,Gelao L.Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities..Cancer Treat Rev2014;40:648-55

[35] Aceto N,Miyamoto DT,Wittner BS.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis..Cell2014;158:1110-22 PMCID:PMC4149753

[36] Jansson S,Larsson AM,Ryden L.Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort..BMC Cancer2016;16:433 PMCID:PMC4938919

[37] Mu Z,Uzan G,Ye Z.Detection and characterization of circulating tumor associated cells in metastatic breast cancer..Int J Mol Sci2016;17: PMCID:PMC5085698

[38] Wang C,Chervoneva I,Ye Z.Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer..Breast Cancer Res Treat2017;161:83-94

[39] Wang J,You CZ,Liu SL.A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer..Cell Mol Biol (Noisy-le-grand).2012;58 Suppl:OL1641-5

[40] Szczerba BM,Vetter M,Gkountela S.Neutrophils escort circulating tumour cells to enable cell cycle progression..Nature2019;566:553-7

[41] Zhang B,He Y,Zhang G.Increased circulating M2-like monocytes in patients with breast cancer..Tumour Biol2017;39:1010428317711571

[42] Adams DL,Alpaugh RK,Tsai S.Circulating giant macrophages as a potential biomarker of solid tumors..Proc Natl Acad Sci U S A2014;111:3514-9 PMCID:PMC3948254

[43] Duda DG,Kohno M,Steller EJ.Malignant cells facilitate lung metastasis by bringing their own soil..Proc Natl Acad Sci U S A2010;107:21677-82 PMCID:PMC3003109

[44] Ishii G,Aoyagi K,Chiba H.Presence of human circulating progenitor cells for cancer stromal fibroblasts in the blood of lung cancer patients..Stem Cells2007;25:1469-77

[45] Jones ML,Pienta KJ.Circulating fibroblast-like cells in men with metastatic prostate cancer..Prostate2013;73:176-81 PMCID:PMC3482413

[46] Ao Z,Machlin LM,Miller PC.Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer..Cancer Res2015;75:4681-7

[47] Tyan SW,Huang CK,Shew JY.Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis..PLoS One2011;6:e15313 PMCID:PMC3020942

[48] Kojima Y,Eaton EN,Scheel C.Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts..Proc Natl Acad Sci U S A2010;107:20009-14 PMCID:PMC2993333